Doctor Filipa Gerardo
Hospital Professor Doutor Fernando Fonseca, Amadora (Portugal)
Member of:
/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
/f/125658/3386x1417/951de003e4/hfa-acronym-name-rgb.png)
Analyzing the economic ramifications of the broad implementation of generic prasugrel
Event: ESC Congress 2024
Topic: Health Economics
Session: Mapping cardiovascular health: risk factors, interventions, and geographic insights
The ESC Grand Quiz Spectacular - case presenters
Event: ESC Congress 2024
Topic: European Society of Cardiology
Session: The ESC Grand Quiz Spectacular
Unveiling the eligibility for screening of cardiac amyloidosis in a real world population
Event: Heart Failure 2024
Topic: Epidemiology, Prognosis, Outcome
Session: Valvular heart disease 4
Single centre 3-year experience in intermittent levosimendan infusion
Event: Heart Failure 2024
Topic: Pharmacotherapy
Session: ePosters in chronic heart failure - pharmacotherapy 5
Unlocking stability: predictors of clinical stability in patients undergoing intermittent levosimendan infusions for advanced heart failure
Event: Heart Failure 2024
Topic: Pharmacotherapy
Session: ePosters in acute heart failure 12
Patiromer in hyperkalemia management: real-world perspective for spironolactone-untreated patients
Event: Heart Failure 2024
Topic: Pharmacotherapy
Session: ePosters in acute heart failure 8
Predicting hospitalizations through post-discharge heart failure appointment: evaluating the FENNIX score's performance
Event: Heart Failure 2024
Topic: Biomarkers
Session: Acute heart failure - diagnostic methods 2
Risk of bleeding in patients with atrial fibrillation: ARC-HBR outperforms HASBLED
Event: Heart Failure 2024
Topic: Epidemiology, Prognosis, Outcome
Session: ePosters in arrhythmias and device therapy 1
Meta-analysis of 3-month vs 12-month dual anti-platelet therapy after percutaneous coronary intervention
Event: ESC Congress 2023
Topic: Pharmacotherapy
Session: Optimal antithrombotic regimen after percutaneous coronary intervention in stable coronary artery disease
Eligibility for acetazolamide in real-world acute heart failure patients
Event: Heart Failure 2023
Topic: Treatment
Session: Chronic heart failure - treatment 5
